The clinical pharmacology of tafenoquine in the radical cure of
Plasmodium vivax
epidemiology
global health
haemolysis
infectious disease
microbiology
radical cure
tafenoquine
Journal
eLife
ISSN: 2050-084X
Titre abrégé: Elife
Pays: England
ID NLM: 101579614
Informations de publication
Date de publication:
06 12 2022
06 12 2022
Historique:
received:
13
09
2022
accepted:
21
11
2022
pubmed:
7
12
2022
medline:
15
12
2022
entrez:
6
12
2022
Statut:
epublish
Résumé
Tafenoquine is a newly licensed antimalarial drug for the radical cure of
Identifiants
pubmed: 36472067
doi: 10.7554/eLife.83433
pii: 83433
pmc: PMC9725750
doi:
pii:
Types de publication
Meta-Analysis
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Wellcome Trust
ID : 200909/Z/16/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 223253/Z/21/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 093956/Z/10/C
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 200909
Pays : United Kingdom
Informations de copyright
© 2022, Watson, Commons et al.
Déclaration de conflit d'intérêts
JW, JS, AL, ML, CC, FN, RP, ND, NW No competing interests declared, RC has received an Emerging Leader Investigator Grant (1194702) from the Australian National Health & Medical Research Council. The author has no other competing interests to declare, JT Joel Tarning has participated on the Novartis Malaria Advisory Council (payments made to their institution) and acts as an ASCPT Infectious Diseases steering committee member. The author has no other competing interests to declare, JG, GK was formerly an employee of GlaxoSmithKline who funded the pre-registration studies of tafenoquine. The author holds stock in GlaxoSmithKline. The author has no other competing interests to declare
Références
Nat Commun. 2019 Dec 6;10(1):5595
pubmed: 31811128
Malar J. 2021 Mar 21;20(1):161
pubmed: 33743731
Nat Commun. 2019 Jul 19;10(1):3226
pubmed: 31324806
PLoS Med. 2021 Apr 23;18(4):e1003535
pubmed: 33891582
JAMA Netw Open. 2018 Aug 3;1(4):e181449
pubmed: 30646129
Malar J. 2012 Apr 27;11:135
pubmed: 22540175
Malar J. 2012 Aug 02;11:259
pubmed: 22856549
BMC Med. 2020 Feb 20;18(1):28
pubmed: 32075649
Lancet. 2014 Mar 22;383(9922):1049-58
pubmed: 24360369
Antimicrob Agents Chemother. 2016 Nov 21;60(12):7321-7332
pubmed: 27697758
Pharmacogenet Genomics. 2020 Sep;30(7):161-165
pubmed: 32433338
Int J Parasitol Drugs Drug Resist. 2017 Aug;7(2):181-190
pubmed: 28384505
Clin Infect Dis. 2018 Oct 30;67(10):1543-1549
pubmed: 29889239
Am J Trop Med Hyg. 1998 May;58(5):645-9
pubmed: 9598455
Behav Genet. 1997 Jul;27(4):325-51
pubmed: 9519560
J Pharmacokinet Pharmacodyn. 2017 Dec;44(6):509-520
pubmed: 28887735
Malar J. 2011 Oct 11;10:297
pubmed: 21989376
Br J Clin Pharmacol. 2022 Jun;88(6):2657-2664
pubmed: 34997616
BMC Med. 2019 Aug 1;17(1):151
pubmed: 31366382
Antimicrob Agents Chemother. 2021 Oct 18;65(11):e0130221
pubmed: 34398667
J Pharmacokinet Pharmacodyn. 2001 Oct;28(5):481-504
pubmed: 11768292
Antimicrob Agents Chemother. 2018 Oct 24;62(11):
pubmed: 30201820
Lancet Microbe. 2021 May;2(5):e175-e176
pubmed: 35544205
J Infect Dis. 1999 Oct;180(4):1282-7
pubmed: 10479159
Am J Trop Med Hyg. 2017 Sep;97(3):702-711
pubmed: 28749773
Lancet. 2019 Sep 14;394(10202):929-938
pubmed: 31327563
Antimicrob Agents Chemother. 2017 Apr 24;61(5):
pubmed: 28289025
Lancet Child Adolesc Health. 2022 Feb;6(2):86-95
pubmed: 34871570
N Engl J Med. 2019 Jan 17;380(3):229-241
pubmed: 30650326
Clin Infect Dis. 2004 Oct 15;39(8):1095-103
pubmed: 15486831
N Engl J Med. 2019 Jan 17;380(3):215-228
pubmed: 30650322
Clin Transl Sci. 2020 Jan;13(1):116-124
pubmed: 31647186
AAPS J. 2011 Jun;13(2):143-51
pubmed: 21302010
Clin Microbiol Rev. 2019 Jul 31;32(4):
pubmed: 31366609
Malar J. 2016 Feb 18;15:97
pubmed: 26888075
Antimicrob Agents Chemother. 2018 Jun 26;62(7):
pubmed: 29661873
PLoS One. 2017 Nov 9;12(11):e0187376
pubmed: 29121061
Clin Infect Dis. 2001 Dec 15;33(12):1968-74
pubmed: 11700577
Malar J. 2017 May 19;16(1):209
pubmed: 28526056